Castle Biosciences(CSTL) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Announced launch of AdvanceAD-Tx™, the Company's test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Q3 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 36% over Q3 2024 ® ® Castle Biosciences Reports Third Quarter 2025 Results Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Conference call and webcast toda ...